African Trypanosomiasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

African Trypanosomiasis Market Outlook

Thelansis’s “African Trypanosomiasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential African Trypanosomiasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

African Trypanosomiasis Overview

African trypanosomiasis, also referred to as human African trypanosomiasis (HAT) or sleeping sickness, is a disease caused by one of two protozoa, Trypanosoma brucei, transmitted by the tsetse fly in sub-Saharan Africa. This illness falls under the category of neglected tropical diseases and poses a significant threat, as it is often fatal if left untreated. Trypanosoma brucei is typically transmitted to humans through the bite of an infected tsetse fly. Once the tsetse fly acquires the trypanosomes, they undergo multiplication and develop into epimastigotes. Humans become infected following a tsetse fly bite, after which the injected parasites rapidly proliferate in the bloodstream and lymphatic system. Ultimately, the parasite infiltrates the central nervous system (CNS), leading to neurological and behavioral symptoms. In some cases, individuals may experience a severe hypersensitivity reaction to the parasite, resulting in itching, swelling, and edema. To detect HAT caused by Trypanosoma brucei gambiense, the card agglutination trypanosoma test (CATT) can be utilized. Management in the early stages necessitates the treatment of symptoms like fever and malaise. Close monitoring of the CNS status is essential, and in severe cases, patients may require intubation and mechanical ventilation to maintain a clear airway. HAT caused by Trypanosoma brucei gambiense is treated differently depending on the disease stage. In the first stage, treatment involves the use of pentamidine. When patients progress to CNS symptoms, they require eflornithine and nifurtimox. If there is no response to these treatments, healthcare providers may consider melarsoprol. For HAT caused by Trypanosoma brucei rhodesiense, the treatment approach varies. In the initial stage, suramin is administered, while in the second stage, melarsoprol is the preferred treatment. If the infection is identified and treated during the early stage, most patients can recover. However, when the patient presents with stage 2 disease, CNS involvement typically leads to a fatal outcome. Presently, the cure rate with the drug melarsoprol exceeds 90%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: